Novo Nordisk CEO Says Weight-Loss Drugs Could Lead the Company Into Longevity and Medical Aesthetics
N.R. Finch
Novo Nordisk CEO Doustdar said on June 7 that new semaglutide research may steer the company into longevity and medical aesthetics — a pivot moment for a firm that still draws over 90% of revenue from diabetes and obesity drugs, under growing investor pressure to diversify.
How does a weight-loss drug lead to longevity?
Novo Nordisk says some studies show semaglutide — the active ingredient in Ozempic and Wegovy — does more than help patients lose weight. It appears to protect the heart, liver, and kidneys.
The key detail: these organ-protection effects showed up before patients lost significant weight. This means → the molecule may work on a deeper level than appetite suppression, potentially slowing disease progression itself.
CEO Doustdar put it bluntly: "If the semaglutide molecule is indeed slowing many of these diseases, then whether we like it or not, we may have entered a battle to extend life."
Why are investors pushing Novo Nordisk to diversify?
Over 90% of Novo Nordisk's revenue comes from diabetes and obesity treatments — an extremely concentrated business. In plain terms = nearly all eggs in one basket.
Rival Eli Lilly spans oncology, immunology, and neuroscience, giving it a far broader product line. This means → as generic competition and pricing pressure intensify, Lilly carries more resilience.
Bloomberg reports that some investors have explicitly asked Novo Nordisk to find new growth paths. Doustdar's remarks at the American Diabetes Association conference were a direct response to that pressure.
How is the Wegovy pill selling?
The Wall Street Journal reported on June 8 that Wegovy's oral weight-loss pill has surpassed 3 million prescriptions since its early-January U.S. launch.
Growth pace: 1 million prescriptions in the first 12 weeks, then another 2 million in the next 10 weeks — clear acceleration.
Over 80% of new prescriptions went to patients who had never used a GLP-1 drug — a class of medicines that mimic gut hormones to control appetite and blood sugar. This means → the pill is pulling new patients into the market, not cannibalizing Novo's own injectable.
What does all of this add up to?
Doustdar said "we have to be obsessed with what the patient wants." This reflects a shift from a "sell the drug" mindset toward building new lanes around patient needs.
Rapid oral-drug uptake proves that format innovation can expand the market; the longevity and aesthetics pitch is about telling a new story for the future.
Put simply = Novo Nordisk holds one trump card — semaglutide — and now needs to prove that card can win more than the weight-loss hand alone.
Content is for reference only, not financial advice.